Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2024-201391

Published: 2024

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Blood (2021) 138 (Supplement 1): 1417.

https://doi.org/10.1182/blood-2021-147822

Published: 2021

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Blood (2019) 134 (Supplement_1): 353.

https://doi.org/10.1182/blood-2019-129835

Published: 2019

Journal Articles

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

Blood (2018) 132 (Supplement 1): 1687.

https://doi.org/10.1182/blood-2018-99-118507

Published: 2018

Journal Articles

Efficacy and Safety of Bendamustine and Rituximab As First Salvage Treatment in Chronic Lymphocytic Leukemia: Results of the Gimema-Eric LLC1315 Study

Blood (2017) 130 (Supplement 1): 4330.

https://doi.org/10.1182/blood.V130.Suppl_1.4330.4330

Published: 2017

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Blood (2015) 126 (23): 2946.

https://doi.org/10.1182/blood.V126.23.2946.2946

Published: 2015

Journal Articles

Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi

Francesco Merli, MD, Stefano Luminari, MD, Caterina Mammi, PhD, Nicola Cascavilla, MD, Alessia Bari, MD, Caterina Stelitano, MD, Renato Scalone, MD, Luca Baldini, Prof, Francesco Angrilli, MD, Giuseppe Polimeno, MD, Paolo G Gobbi, Prof, Giulia Cervetti, MD, Fiorella Ilariucci, MD, Alessia Ruffini, Luigi Marcheselli, Massimo Federico, MD

Blood (2014) 124 (21): 499.

https://doi.org/10.1182/blood.V124.21.499.499

Published: 2014

Journal Articles

Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Annalisa Arcari, MD, Annalisa Chiappella, MD, Vanessa Valenti, Luca Zanlari, MD, Monica Tani, MD, Roberto Marasca, MD, Maria Giuseppina Cabras, MD, Michele Spina, MD, Alberto Santagostino, MD, Fiorella Ilariucci, MD, Giuseppe Carli, MD, Pellegrino Musto, MD, Paolo Savini, MD, Dario Marino, MD, Francesco Ghio, MD, Massimo Gentile, MD, Maria Christina Cox, MD, Roberta Della Seta, MD, Daniele Vallisa, MD

Blood (2014) 124 (21): 3074.

https://doi.org/10.1182/blood.V124.21.3074.3074

Published: 2014

Journal Articles

Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study

Pier Luigi Zinzani, MD, PhD, Stefano Luminari, MD, Francesco Merli, Emanuela Anna Pesce, Stephane Chauvie, Cinzia Pellegrini, Luigi Marcheselli, Isabella Capodanno, MD, Fiorella Ilariucci, Massimiliano Salati, Lisa Argnani, PhD, Massimo Federico

Blood (2014) 124 (21): 3088.

https://doi.org/10.1182/blood.V124.21.3088.3088

Published: 2014

Journal Articles

Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukemia

Blood (2014) 124 (21): 3314.

https://doi.org/10.1182/blood.V124.21.3314.3314

Published: 2014

Journal Articles

High-Throughput Sequencing For The Identification Of NOTCH1 mutations In Early Stage Chronic Lymphocytic Leukemia: Biological and Clinical Implications

Blood (2013) 122 (21): 1622.

https://doi.org/10.1182/blood.V122.21.1622.1622

Published: 2013

Journal Articles

Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09)

Stefano Luminari, MD, Maria Cecilia Goldaniga, MD, Marina Cesaretti, Lorella Orsucci, Alessandra Tucci, MD, Alessandro Pulsoni, MD, Flavia Salvi, MD, Angelo Michele Carella, Alessandra Tedeschi, MD, Antonio Pinto, MD, Caterina Stelitano, Daniele Vallisa, MD, Fiorella Ilariucci, MD, Michele Spina, Luca Arcaini, Luigi Marcheselli, MS, Massimo Federico, MD, Luca Baldini

Blood (2013) 122 (21): 3049.

https://doi.org/10.1182/blood.V122.21.3049.3049

Published: 2013

Journal Articles

The Pro-Inflammatory IL23/IL23R/IL17 Axis Is Active in IL23R-Expressing Circulating CLL Cells in Patients with Poor Prognosis

Fortunato Morabito, MD, Giovanna Cutrona, PhD, Anna Grazia Recchia, PhD, Sonia Fabris, PhD, Serena Matis, PhD, Monica Colombo, PhD, Sabrina Bossio, Massimo Gentile, MD, Carlotta Massucco, PhD, Laura De Stefano, Stefano Molica, MD, Caterina Musolino, MD, Fiorella Ilariucci, Gianluca Festini, MD, Francesco Di Raimondo, MD, Pierfrancesco Tassone, MD, Antonino Neri, Claudio Tripodo, MD, Manlio Ferrarini, MD

Blood (2012) 120 (21): 3889.

https://doi.org/10.1182/blood.V120.21.3889.3889

Published: 2012

Journal Articles

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial

Andrés J. M. Ferreri, Silvia Govi, Markus Raderer, Antonino Mulè, Alessandro Andriani, Daniele Caracciolo, Liliana Devizzi, Fiorella Ilariucci, Stefano Luminari, Edi Viale, Leonhard Müllauer, Stefania Dell'Oro, Paolo Giorgio Arcidiacono, Maurilio Ponzoni, Caterina Patti

Blood (2012) 120 (18): 3858–3860.

https://doi.org/10.1182/blood-2012-06-438424

Published: 2012

NARROW

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

Efficacy and Safety of Bendamustine and Rituximab As First Salvage Treatment in Chronic Lymphocytic Leukemia: Results of the Gimema-Eric LLC1315 Study

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi

Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study

Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukemia

High-Throughput Sequencing For The Identification Of NOTCH1 mutations In Early Stage Chronic Lymphocytic Leukemia: Biological and Clinical Implications

Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09)

The Pro-Inflammatory IL23/IL23R/IL17 Axis Is Active in IL23R-Expressing Circulating CLL Cells in Patients with Poor Prognosis

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only